NCT lookup

Inclusion Criteria:

* Capable of understanding and willing to provide signed and dated written voluntary informed consent (and any local or national authorization requirements) before any protocol-specific procedures are performed.
* Male or female subjects at least 12 years old and in good general health.
* Able to complete the study and to comply with study instructions.
* Moderate plaque-type psoriasis on the body (excluding the scalp and face) defined as:

  * Plaque-type psoriasis involving 3% to 10% of total body surface area (BSA).
  * An Investigator's Static Global Assessment (ISGA) score of 3 at Baseline.
  * Identification of a target lesion (\>2 cm²) on the trunk or extremities with a score of 2 or 3 (0-5 scale) for erythema, scaling and plaque thickness. Lesions on the palms/soles, knees, elbow, and intertriginous areas should not be used as the target lesion site.
* Involvement of at least 10% of the total scalp surface area with clinical signs (erythema, thickness, and scaliness) rated as moderate (3) based on the ISGA.
* Negative urine pregnancy test for females of childbearing potential. • Sexually active females of childbearing potential participating in the study must agree to use a medically acceptable method of contraception while receiving protocol-assigned product. A woman of childbearing potential is defined as one who is biologically capable of becoming pregnant; including perimenopausal women who are fewer than 2 years from their last menses.

Exclusion Criteria:

* Any subject who has participated in any previous calcipotriene foam clinical.
* Female who is pregnant, trying to become pregnant, or breastfeeding.
* Known allergy or other adverse reaction to calcipotriene or other vitamin D analogs; or to any component of the investigational formulations.
* History of hypercalcemia or of vitamin D toxicity.
* Other serious skin disorder or any chronic medical condition that is not well-controlled.
* Use of nonbiologic systemic anti-psoriatic therapy (eg, corticosteroids, psoralen combined with exposure to ultraviolet light A \[PUVA\], ultraviolet light B \[UVB\], retinoids, methotrexate, cyclosporine, other immunosuppressive agents) within 4 weeks prior to enrollment.
* Systemic treatment with biological therapies (marketed or not marketed) with a possible effect on psoriasis within 4 weeks (etanercept), 2 months (adalimumab, alefacept, infliximab), 4 months (ustekinumab) or 4 weeks/5 half-lives (whichever is longer) for experimental products prior to randomization.
* Use of topical therapies that have a known beneficial effect on psoriasis, including but not limited to corticosteroids, retinoids, Vitamin D derivatives, coal tar, or anthralin, within 2 weeks prior to enrollment.
* Systemic medications for other medical conditions that are known to affect psoriasis (eg, lithium, beta adrenergic blockers) within 4 weeks prior to enrollment.
* Use of any investigational product within 4 weeks prior to enrollment, currently participating in another clinical trial, or plans to receive an investigational product during the study.
* Current drug or alcohol abuse (drug screening not required).
* Has a history of any immuno-compromizing disease.
* Any other condition that, in the judgment of the investigator, would put the subject at unacceptable risk for participation in the study.
* Employees of the investigator; study center; or Stiefel, a GSK company involved in the study; or an immediate family member (eg, partner, offspring, parents, siblings or sibling's offspring) of an employee involved in the study.

• Tucson, Arizona, United States
• San Diego, California, United States
• Denver, Colorado, United States
• North Miami Beach, Florida, United States
• Newnan, Georgia, United States
• Snellville, Georgia, United States
• Louisville, Kentucky, United States
• Louisville, Kentucky, United States
• Detroit, Michigan, United States
• Warren, Michigan, United States
• Fridley, Minnesota, United States
• St Louis, Missouri, United States
• New York, New York, United States
• Rochester, New York, United States
• High Point, North Carolina, United States
• Winston-Salem, North Carolina, United States
• Cincinnatti, Ohio, United States
• Portland, Oregon, United States
• Mt. Pleasant, South Carolina, United States
• Knoxville, Tennessee, United States
• Nashville, Tennessee, United States
• Austin, Texas, United States
• Houston, Texas, United States
• San Antonio, Texas, United States
• Salt Lake City, Utah, United States
• Lynchburg, Virginia, United States